Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Gene Therapy00:59

Gene Therapy

27.6K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
27.6K
Group Therapy01:26

Group Therapy

417
Group therapy is a sociocultural approach to psychological treatment, where individuals with shared psychological challenges come together under the guidance of a mental health professional. This therapeutic modality offers unique opportunities for individuals to connect, share, and grow within the context of a supportive group. By fostering mutual understanding and collaboration, group therapy can address a range of psychological concerns effectively, often complementing or surpassing the...
417
Psychodynamic Therapy01:29

Psychodynamic Therapy

549
Psychodynamic therapies emphasize the exploration of unconscious processes and early childhood experiences as fundamental contributors to psychological difficulties. These therapies, deeply rooted in Freud's psychoanalytic theory, aim to uncover and resolve unconscious conflicts, granting individuals insights that promote emotional and behavioral healing. Contemporary psychodynamic approaches have evolved, integrating a broader range of influences and methodologies while still valuing the...
549
Humanistic Therapy01:24

Humanistic Therapy

348
Humanistic therapies emphasize personal growth, self-understanding, and the fulfillment of human potential. Rooted in the belief that individuals inherently strive toward self-actualization, these approaches encourage clients to explore their feelings and experiences in a supportive, nonjudgmental environment. Humanistic therapies differ from psychodynamic approaches by focusing on conscious experiences, present circumstances, and the potential for self-improvement rather than past conflicts...
348
Modeling in Therapy01:26

Modeling in Therapy

427
Modeling, a key technique in therapy, uses observational learning to help clients acquire and practice new skills by watching therapists demonstrate desired behaviors. This approach, rooted in Albert Bandura's concept of vicarious learning, plays a significant role in therapeutic interventions for various psychological conditions, including social anxiety, ADHD, and depression.
Participant Modeling
Participant modeling involves therapists demonstrating calm and effective behaviors in...
427
Couples Therapy01:26

Couples Therapy

292
Couples therapy is a therapeutic approach designed to help individuals in intimate relationships address conflicts, improve communication, and foster healthier dynamics. It is appropriate for couples at various stages, including those who are dating, married, or in long-term partnerships, and aims to support partners in navigating their unique relational challenges.
Core Principles and Techniques
Couples therapy often incorporates cognitive-behavioral principles to identify and modify negative...
292

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lipoprotein apheresis in the era of new lipid-lowering therapies.

European heart journal·2026
Same author

Effects of micro/nanoplastics combined with three anthropogenic chemicals on larval zebrafish (Danio rerio): study of toxicity, behaviour and assessment of uptake.

NanoImpact·2026
Same author

Pelacarsen and lipoprotein(a) apheresis in secondary prevention: the Lp(a)FRONTIERS APHERESIS trial.

European heart journal·2026
Same author

Physician and patient perspectives on the treatment of hypercholesterolaemia: a cross-sectional study to identify disconnects.

Current medical research and opinion·2025
Same author

Evaluation of phenotypic and behavioral toxicity of micro- and nano-plastic polystyrene particles in larval zebrafish (Danio rerio).

Toxicological sciences : an official journal of the Society of Toxicology·2025
Same author

Evolocumab-Based LDL-C Management in High and Very High Cardiovascular Risk Patients in German Clinical Practice: The HEYMANS Study.

Advances in therapy·2024
Same journal

Lipoprotein(a).

Clinical research in cardiology supplements·2019
Same journal

Lipoprotein(a) apheresis in patients with peripheral arterial disease: rationale and clinical results.

Clinical research in cardiology supplements·2019
Same journal

Prediction of cardiovascular risk by Lp(a) concentrations or genetic variants within the LPA gene region.

Clinical research in cardiology supplements·2019
Same journal

Lipoprotein(a)-an interdisciplinary challenge.

Clinical research in cardiology supplements·2019
Same journal

Lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 inhibitors.

Clinical research in cardiology supplements·2019
Same journal

Lipoprotein(a) and mortality-a high risk relationship.

Clinical research in cardiology supplements·2019
See all related articles

Related Experiment Video

Updated: Jan 28, 2026

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

12.4K

Lipoprotein(a)-antisense therapy.

Anja Vogt1

  • 1Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Ziemssenstraße 1, 80336, Munich, Germany. Anja.Vogt@med.uni-muenchen.de.

Clinical Research in Cardiology Supplements
|March 13, 2019
PubMed
Summary
This summary is machine-generated.

Elevated lipoprotein(a) (Lp(a)) increases cardiovascular disease risk. New antisense oligonucleotide therapies show significant Lp(a) reduction, offering hope for future cardiovascular event prevention.

Keywords:
Antisense oligonucleotidesAtherosclerosisCardiovascular diseaseLDL-CholesterolLipid lowering therapy

More Related Videos

Isolation of High-density Lipoproteins for Non-coding Small RNA Quantification
10:39

Isolation of High-density Lipoproteins for Non-coding Small RNA Quantification

Published on: November 28, 2016

11.8K
Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy
10:30

Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy

Published on: May 24, 2016

19.2K

Related Experiment Videos

Last Updated: Jan 28, 2026

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

12.4K
Isolation of High-density Lipoproteins for Non-coding Small RNA Quantification
10:39

Isolation of High-density Lipoproteins for Non-coding Small RNA Quantification

Published on: November 28, 2016

11.8K
Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy
10:30

Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy

Published on: May 24, 2016

19.2K

Area of Science:

  • Cardiology
  • Genetics
  • Pharmacology

Background:

  • Elevated lipoprotein(a) (Lp(a)) is a significant risk factor for early and severe cardiovascular disease (CVD).
  • Current lipid-modifying therapies, except niacin, do not effectively lower Lp(a), and endpoint trial data is lacking for niacin.
  • Lipoprotein apheresis effectively reduces Lp(a) levels and cardiovascular events, but is invasive.

Purpose of the Study:

  • To evaluate the efficacy and safety of a novel hepatospecific Apo(a) antisense oligonucleotide (IONIS-APO(a)-LRx) for lowering Lp(a).
  • To assess the potential of specific Lp(a) lowering as a therapeutic strategy for cardiovascular risk reduction.

Main Methods:

  • Phase 2 clinical trial of IONIS-APO(a)-LRx in patients with elevated Lp(a).
  • Administration of varying dosages of the antisense oligonucleotide.
  • Monitoring of Lp(a) levels, safety, and tolerability, including injection site reactions.

Main Results:

  • High dosages of IONIS-APO(a)-LRx achieved substantial Lp(a) reductions of 72% and 80%.
  • Achieved Lp(a) levels below 50 mg/dL in 81% and 98% of participants at highest dosages.
  • The drug demonstrated good tolerability and safety, with injection site reactions as the most common side effect.

Conclusions:

  • The hepatospecific Apo(a) antisense oligonucleotide IONIS-APO(a)-LRx demonstrates potent and specific Lp(a) lowering capabilities.
  • These findings support the potential of this novel therapy for reducing cardiovascular risk in individuals with elevated Lp(a).
  • Further Phase 3 trials are anticipated to confirm these results and demonstrate cardiovascular event reduction.